OCEA-101 (CSPG4 mAb)

About Ocean Biomedical

Ocean Biomedical operates as a biopharmaceutical accelerator, bridging the gap between foundational academic research and clinical development. Its strategy centers on identifying and in-licensing promising early-stage discoveries from institutions like Brown University, then advancing them through preclinical and clinical stages. While the model offers a diversified pipeline targeting oncology, fibrosis, and infectious diseases, the company is pre-revenue and faces significant challenges, including a severely depressed stock price and the inherent risks of early-stage development. Its future hinges on demonstrating clear clinical proof-of-concept for its lead assets to attract capital and partnerships.

Therapeutic Areas